Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

ASTELLAS PHARMA EUROPE B.V.

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Drug-drug Interaction Study With MDV3100 (ASP9785) and Gemfibrozil and Itraconazole

Phase 1

Completed

Conditions: Healthy Subjects
Pharmacokinetics
Drug-Drug Interaction

Interventions: Drug: MDV3100
Drug: Itraconazole
Drug: Gemfibrozil

First Posted Date: 2013-08-01

Last Posted Date: 2013-08-01

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 41

Registration Number: NCT01913379

Locations: 🇫🇷
SGS, Paris, France

A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy Subjects
Castration Resistant Prostate Cancer (CRPC)
Relative Bioavailability
MDV3100

Interventions: Drug: MDV3100

First Posted Date: 2013-07-30

Last Posted Date: 2013-07-30

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 55

Registration Number: NCT01911741

Locations: 🇩🇪
Parexel International GmbH, Berlin, Germany

A Study to Explore the Routes of Elimination of MDV3100

Phase 1

Completed

Conditions: Healthy Subjects
Pharmacokinetics of MDV3100

Interventions: Drug: MDV3100

First Posted Date: 2013-07-30

Last Posted Date: 2013-07-30

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 6

Registration Number: NCT01911715

Locations: 🇳🇱
PRA International, Zuidlaren, Netherlands

Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates

Phase 1

Completed

Conditions: Castration Resistant Prostate Cancer (CRPC)
Pharmacokinetics of MDV3100

Interventions: Drug: MDV3100
Drug: Pioglitazone
Drug: Warfarin
Drug: Omeprazole
Drug: Midazolam

First Posted Date: 2013-07-30

Last Posted Date: 2017-06-26

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 14

Registration Number: NCT01911728

Locations: 🇿🇦
Parexel, George, South Africa
🇿🇦
Parexel/Qdot Pharma, Port Elizabeth, South Africa

Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients

Phase 1

Completed

Conditions: Pharmacokinetics of Enzalutamide
Prostate Cancer

Interventions: Drug: Enzalutamide capsule
Drug: Enzalutamide tablet

First Posted Date: 2013-07-18

Last Posted Date: 2014-09-09

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 27

Registration Number: NCT01902251

Locations: 🇺🇸
University of Colorado - Anschutz Medical Campus, Denver, Colorado, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

and more 1 locations

Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group

Phase 1

Completed

Conditions: Pharmacokinetics of MDV3100
Kidney Diseases
Healthy Subjects

Interventions: Drug: MDV3100

First Posted Date: 2013-07-17

Last Posted Date: 2014-09-15

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 33

Registration Number: NCT01901133

Locations: 🇲🇩
Arensia, Chisinau, Moldova, Republic of

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis

Phase 3

Completed

Conditions: Anemia in Chronic Kidney Disease in Non-dialysis Patients

Interventions: Drug: Placebo
Drug: Roxadustat

First Posted Date: 2013-06-27

Last Posted Date: 2024-11-14

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 594

Registration Number: NCT01887600

Locations: 🇧🇾
Site BY37503, Brest, Belarus
🇧🇾
Site BY37504, Gomel, Belarus
🇧🇾
Site BY37501, Grodno, Belarus

and more 135 locations

A Study to Assess the Safety, Tolerability and Effects of Single Ascending Doses of ASP3652 in Healthy Subjects

Phase 1

Completed

Conditions: Pharmacokinetics
Pharmacodynamics
Healthy Subjects
Safety

Interventions: Drug: ASP3652
Drug: Placebo

First Posted Date: 2013-03-21

Last Posted Date: 2013-03-21

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 26

Registration Number: NCT01815684

Locations: 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands

Treatment of Symptoms in Male Patients With Lower Urinary Tract Symptoms (LUTS) Predominant Storage Symptoms (Overactive Bladder Syndrome)

Completed

Conditions: Lower Urinary Tract Predominant Storage Symptoms

Interventions: Drug: Solifenacin

First Posted Date: 2013-02-27

Last Posted Date: 2013-12-19

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 86

Registration Number: NCT01799902

Locations: 🇧🇪
ASZ, Aalst, Belgium
🇧🇪
ZNA Stuyvenberg, Antwerpen, Belgium
🇧🇪
Erasme, Brussel, Belgium

and more 12 locations

A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects

Phase 1

Completed

Conditions: Drug-Drug Interaction (DDI)
Healthy Subjects

Interventions: Drug: ASP3652
Drug: Gemfibrozil
Drug: Repaglinide

First Posted Date: 2013-02-22

Last Posted Date: 2013-02-22

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 48

Registration Number: NCT01797198

Locations: 🇬🇧
PAREXEL Early Phase Clinical Unit, Harrow, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy